News

Jul 10, 2020

As an ever-increasing number of complex surgeries are regularly being performed in an outpatient setting at ambulatory surgical centers, some brain tumor resections may be safe and feasible for appropriately selected patients, new research suggests. Unadjusted results from a large feasibility study that included more than 300 patients who underwent craniotomy for resection of meningioma showed that among those who were treated in an outpatient setting, mortality and complication rates were significantly lower than for their inpatient counterparts.

Jul 10, 2020

Scientists are ready to try a new cancer vaccine in humans following the successful outcome of their preclinical studies. The new vaccine was developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland. Lead Researcher Associate Professor Kristen Radford says the vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.

Jul 10, 2020

Indiana University School of Medicine researchers Milan Radovich, Ph.D., and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple-negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival. 

Journal Abstracts

Jul 10, 2020

Marcel P. Trefny et.al. conducted a study to assess that ntratumoral Natural killer cells from Non-Small Cell Lung Cancer patients expressed elevated levels of the immune checkpoint receptor PD-1 on their cell surface. The researchers concluded that therapeutic potential of PD-1+ Natural killer cells in immune checkpoint blockade and could guide the development of Natural killer cell-stimulating agents in combination with PD-1 blockade.

Jul 10, 2020

Alec Britt et.al. conducted a study to assess if poor outcomes extend to patients with all types of ch17 abnormalities and the impact of concomitant TP53 gene mutations assessed by next-generation sequencing on prognosis. The researchers concluded that AML/MDS patients with ch17 abnormalities have poor outcomes with or without hematopoietic cell transplant . The results show that patients with ch17 abnormalities and TP53 mutations have a significantly poorer survival compared to patients who have ch17 abnormalities but no TP53 mutations.

Jul 10, 2020

Aaron D.Goldberg et.al. conducted a study to safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed/refractory acute lymphoblastic leukemia/acute myeloid leukemia. The researchers concluded that  signal for serious immune-related adverse eventss such as Guillain-Barré syndrome/polyradiculopathy was observed and there was no evidence of immunogenicity. PK showed rapid clearance with apparent half-life <2 days for conjugated and total antibody, suggesting that Q3W dosing may be insufficient for therapeutic efficacy, and prompting exploration of a QW schedule. 

Recent Articles

Jul 10, 2020

Lung cancer is the most commonly diagnosed cancer worldwide and the leading cause of cancer-related deaths, killing more per year than breast, colon, and prostate cancers combined. Over the years, studies of the lung cancer genome have fueled the development of drug therapies that target mutations in specific genes and pathways. But despite these advances, survival among lung cancer patients remains low (below 20 percent).

Jul 10, 2020

Scientists are ready to try a new cancer vaccine in humans following the successful outcome of their preclinical studies. The new vaccine was developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland. Lead Researcher Associate Professor Kristen Radford says the vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.

Jul 10, 2020

Indiana University School of Medicine researchers Milan Radovich, Ph.D., and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple-negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival. 

Clinical Research

Jun 01, 2020

The purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.

Jun 01, 2020

This research study is being done to understand how patients with chronic cancer pain take their long-acting opioid medications and to develop an intervention to enhance cancer pain management.

Feb 27, 2020

Christopher G. Brennan-Jones et.al. identified specific strategies which have shown effectiveness in reducing workplace noise. These include implementation of stricter legislation and also stress upon the need for training in the proper use of earplugs and earmuffs so as to reduce noise exposure to safe levels. 

Feb 27, 2020

Christopher G. Brennan-Jones et.al. identified specific strategies which have shown effectiveness in reducing workplace noise. These include implementation of stricter legislation and also stress upon the need for training in the proper use of earplugs and earmuffs so as to reduce noise exposure to safe levels. 

Feb 27, 2020

Daniel G. Whitney et.al. conducted a study to determine prevalence of major noncommunicable diseases in young adults with pediatric-onset disabilities and compared it in adults without pediatric onset disabilities. The researchers found that young adults with pediatric onset disabilities showed an early onset of several noncommunicable diseases. They were contributors to global and national burden of disease and mortality.

Jan 31, 2020

This study investigates whether 1) Silver diamine fluoride (SDF) application using Super Floss can arrest and/or reverse initial interproximal caries on primary molars and 2) whether SDF applied with Super Floss is more effective in arresting or remineralizing initial interproximal lesion in comparison to SDF applied without Super Floss or fluoride varnish applied alone.

Jan 31, 2020

This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY1163877.

Publications

Jun 26, 2020

In patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), a once-daily oral regimen of ibrutinib and venetoclax was associated with deep molecular remissions in both bone marrow and peripheral blood, including in patients with high-risk disease, according to investigators in phase 2 CAPTIVATE MRD trial.

Jun 04, 2020

Georgios Tsakonas et.al. conducted a study to understand the alterations in gene expression in brain metastasis versus primary tumour as it may increase aggressiveness and impair therapeutic efforts. The researchers concluded  identified a unique gene downregulation pattern in brain metastases compared with primary tumours. This finding may explain the lower intracranial efficacy of systemic therapy, especially immunotherapy, in brain metastasis of patients with non–small-cell lung cancer. 

Jun 01, 2020

Advance in Cancer Prevention addresses all types of cancer, how cancer forms in the body, and their prevention. It focuses on Cancer Vaccines, Chemotherapy, Radioactive Iodine Therapy, Breast Reconstruction Surgery, Mammography, Chemoprevention, aromatase inhibitors, Scintimammography, Oncoplastic surgery, Sumoylation, Dietary Supplements, Cancer Screening, Cancer and Nutrition, Exercise and Cancer, Alternative Cancer Medicines, Stem cell transplants for cancer prevention, Naturopathic Treatments, Clinical Naturopathy, Cancer Prevention from nuts.

Jan 29, 2020

This highly respected and frequently cited journal is a prime source of information in the area of fetal and neonatal research. Original papers present research on all aspects of neonatology, fetal medicine and developmental biology. These papers encompass both basic science and clinical research including randomised trials, observational studies and epidemiology.

Jan 29, 2020

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents. Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes. 

Jan 29, 2020

Journal of Diabetes Investigation is the core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes. The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. The Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology.

Jan 29, 2020

Hepatobiliary Surgery and Nutrition focuses on new findings in hepatopancreatobiliary disease and nutrition, and to provide current and practical information on diagnosis, prevention and clinical investigations. Specific areas of interest include, but not limited to, surgical techniques, clinical and basic researches, transplantation and other therapies, NASH, NAFLD, targeted drug, gut microbiota, metabolism, cancer immunity, genomics, nutrition and dietetics, etc.

Videos

Jul 10, 2020

Watch Dr. Jamie Studts discuss the quality implementation of lung cancer screening and share his thoughts on optimizing community-based implementation.
 

Jul 03, 2020

 

This is a recording of the American Lung Association’s Lung Cancer Precision Medicine Summit which took place on June 18, 2020. Oncologists Dr. Erin Schenk and Dr. Ibiayi Dagogo-Jack discuss which precision medicine treatment is available for lung cancer patients and promising new research. Carly Ornstein, National Director of Lung Cancer Education, gives a high-level overview of precision medicine and discusses new resources.

Jul 03, 2020

 

This is a recording of the American Lung Association’s Lung Cancer Precision Medicine Summit which took place on June 18, 2020. Oncologists Dr. Erin Schenk and Dr. Ibiayi Dagogo-Jack discuss which precision medicine treatment is available for lung cancer patients and promising new research. Carly Ornstein, National Director of Lung Cancer Education, gives a high-level overview of precision medicine and discusses new resources.

Jul 03, 2020

Dr. Pasi Janne, Director of Dana-Farber Cancer Institute’s Lowe Center for Thoracic Oncology and Belfer Center for Applied Cancer Science, and colleagues discuss how COVID-19 is changing the screening, management, and treatment of thoracic cancer, including:

  • The impact on lung cancer screening
  • The role of telemedicine in caring for cancer patients
  • Managing clinical trials 

Case Studies

Jun 24, 2020

Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation. It has many complications and it might increase the risk of other tumors. However, it does not cause hypercalcemia and is rarely associated with parathyroid adenoma. Ahmed M. Abdalhadi and Mohamed A. Yassin report on a 64-year-old female with polycythemia vera found to have hypercalcemia due to parathyroid adenoma.

Jun 22, 2020

Durvalumab, a programmed cell death ligand 1 inhibitor, induces various immune-related adverse events (irAEs), including lung injury. However, diffuse alveolar hemorrhage (DAH) is a rare type of lung injury due to immune checkpoint inhibitors. A 76-year-old man with c-stage IIIA squamous cell carcinoma of the lung received maintenance durvalumab therapy after chemoradiotherapy. He developed dyspnea and malaise after 11 cycles of durvalumab. Chest computed tomography showed rapidly spreading bilateral ground-glass opacity in the lungs. We diagnosed DAH by hemosiderin-laden macrophages in bloody bronchoalveolar lavage fluid. Despite mechanical ventilation, steroids, and cyclophosphamide, he died of respiratory failure. The autopsy revealed that fresh and old bleeding areas coexisted, and neither pulmonary vasculitis nor diffuse alveolar damage was detected microscopically. Furthermore, CD3+ and CD8+ lymphocytes were observed in the lung interstitium, whereas CD20+ and CD4+ lymphocytes were scarcely detected. We report the first case of durvalumab-induced DAH. We should be alert to irAEs with DAH as a potential differential diagnosis of lung injury during durvalumab treatment.

Jun 19, 2020

Only three cases of patients suffering from a localized chronic form of Langerhans cell histiocytosis (LCH) successfully treated with radiofrequency ablation (RFA) have been published so far. This is the first case report of a patient with a localized chronic form of LCH of the femur, which was successfully treated with percutaneous image-guided RFA, and who was evaluated pre-RFA and followed up post-RFA for a period of 48 months, in order to validate the safety and efficacy of this method and to obtain imaging studies depicting the actual in situ changes taking place post-RFA. RFA was proved to be a safe and efficient method when treating patients with a localized chronic form of LCH.

Jun 19, 2020

Recent data suggest that BRCA mutation carriers younger than 40 may not benefit from mammography in addition to MRI. Our objective was to evaluate screening modalities utilized in a high-risk population. Clinicopathologic data were abstracted for patients followed in a high-risk clinic from 2007 to 2017.  Three patients were diagnosed younger than 40, 1 on a mammogram, and 2 on MRI. The patient diagnosed on mammogram had no prior MRI and the lesion was seen on follow-up MRI. Interval screening MRI identified DCIS in BRCA patients with a previous normal mammogram and cancers diagnosed on mammograms were all identified on follow-up MRI. These findings support further evaluation of MRI alone until age 40 in BRCA mutation carriers.